AXL in Myeloid Malignancies
Author Information
Author(s): Pia Aehnlich, Katharina Leuchte, Claudia Schöllkopf, Sara Fresnillo Salo, Tina J. Seremet, Estrid Høgdall, Özcan Met, Kirsten Grønbaek, Per Thor Straten
Primary Institution: Copenhagen University Hospital
Hypothesis
Does AXL expression in myeloid neoplasms affect the efficacy of AXL inhibitors?
Conclusion
The study found unexpectedly low AXL expression in bone marrow myeloblasts from patients with myeloid neoplasms.
Supporting Evidence
- AXL expression was generally absent or very low in AML myeloblasts.
- AXL was undetectable in 20 out of 25 patients.
- Previous studies linked AXL overexpression to poor prognosis in AML.
Takeaway
This study looked at a protein called AXL in blood cancer cells and found that it was mostly missing, which means treatments targeting AXL might work differently than expected.
Methodology
The study assessed AXL expression in AML cell lines and bone marrow myeloblasts using flow cytometry.
Limitations
The study only included a small number of patients and focused on specific cancer types.
Participant Demographics
All patients were above 18 years of age, with 22 having AML, 2 CML in blast crisis, and 1 CMML transformed into AML.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website